Convert Catalysts into Profits: Sagient Research's Edward Stopke

Print E-mail
By Peter Byrne of The Life Sciences Report   
Friday, 23 January 2015 11:54
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner.

Read more...
 

What's Next for Biotech in 2015?

Print E-mail
By The Life Science Report   
Thursday, 15 January 2015 08:42
Are life sciences stocks in a bubble? Will this be the year biotech overshadows big pharma?
Read more...
 

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off

Print E-mail
By Sharon di Stefano   
Monday, 12 January 2015 19:19

When peer-reviewed scientific articles publish, especially for investigational medicine, doctors and investors take notice. Few other accolades are held in such high esteem.

Read more...
 

Where Do Cures Reside? Morrie Ruffin and Michael Werner of the Alliance for Regenerative Medicine Think the Answer Is in Regenerative Medicine

Print E-mail
By George S. Mack of The Life Sciences Report   
Thursday, 08 January 2015 18:07

The practice of medicine is being transformed. The journey has been arduous, but revolutionary stem cell, gene and immunocellular therapies are rapidly moving toward pivotal milestones—and investors in the space should strap in for a rewarding joy ride.

Read more...
 

Q&A: Actinium Pharmaceuticals Inc. CEO Eyes Orphan Drug Application for Flagship Drug

Print E-mail
By M.E.Garza   
Wednesday, 07 January 2015 00:00

Actinium Pharmaceuticals Inc. a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers announced last month that the US Food and Drug Administration (FDA) had granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60.

Read more...
 

Pluristem’s Immunotherapy Breakthrough Could Fast-Track GvHD Studies under Japanese Legislation

Print E-mail
By Sharon di Stefano   
Friday, 02 January 2015 16:20

With data in hand that shows evidence its PLX cell therapy produces an immune response, Pluristem Therapeutics (PSTI:NASDAQ) enters the exploding area of immunotherapy, or treating disease via manipulation of the human immune system, and joins the ranks of its larger pharmaceutical counterparts in an industry estimated at $35 billion with fast growth expected in the next seven to eight years.

Read more...
 

Will Biotech Fire on All Cylinders in 2015?

Print E-mail
By Tracy Salcedo-Chourré of The Life Sciences Report   
Tuesday, 30 December 2014 21:13
Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication.
Read more...
 

Cell Therapy 2015: With Maturity Comes Promise

Print E-mail
By Staff and Wire Reports   
Tuesday, 23 December 2014 22:33
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy—a disruptive technology that has, in the past few years, progressed out of preclinical studies and into clinical development.
Read more...
 

Doug Loe: Canada Has Earned Its Spot in the Biotech All-Star Team Photo

Print E-mail
By Staff and Wire Reports   
Friday, 19 December 2014 08:49
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada.
Read more...
 

When Considering Cell Therapy Investments - Not All Cells Are the Same Q&A with Zami Aberman, Pluristem Therapeutics

Print E-mail
By M.E.Garza   
Wednesday, 17 December 2014 19:54
BioMedReports.com’s editor, M.E. Garza, spoke with Pluristem CEO, Zami Aberman, a leading developer of placenta-based cell therapy products, regarding clear differentiators between cell therapies and why the cell manufacturing process is key. 
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 49

Newsletter

BioMedReports Nevro Receives Approvable Letter From FDA for Senza; KYTHERA Announces Date of FDA Advisory Committee Review o... http://t.co/oLNjguSJjK
BioMedReports Hansen Announces Completion of World's First Intravascular Robot-Assisted IVC Filter Retrieval; Alexza Initiat... http://t.co/VqsIUlA2aM
BioMedReports Minerva Reports Positive Phase 1 Data With MIN-202; Integra Launches Integra(R) Reinforcement Matrix: Below is... http://t.co/opIqtkjZXe